These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35745053)

  • 1. AddictedChem: A Data-Driven Integrated Platform for New Psychoactive Substance Identification.
    Han M; Liu S; Zhang D; Zhang R; Liu D; Xing H; Sun D; Gong L; Cai P; Tu W; Chen J; Hu QN
    Molecules; 2022 Jun; 27(12):. PubMed ID: 35745053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profile, effects, and toxicity of novel psychoactive substances: A systematic review of quantitative studies.
    Assi S; Gulyamova N; Ibrahim K; Kneller P; Osselton D
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28631432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decline in new psychoactive substance use disorders following legislation targeting headshops: Evidence from national addiction treatment data.
    Smyth BP; Lyons S; Cullen W
    Drug Alcohol Rev; 2017 Sep; 36(5):609-617. PubMed ID: 28419577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current European data collection on emergency department presentations with acute recreational drug toxicity: gaps and national variations.
    Heyerdahl F; Hovda KE; Giraudon I; Yates C; Dines AM; Sedefov R; Wood DM; Dargan PI
    Clin Toxicol (Phila); 2014 Dec; 52(10):1005-12. PubMed ID: 25361166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of the effects of novel psychoactive substances 'legal highs' on people with severe mental illness.
    Gray R; Bressington D; Hughes E; Ivanecka A
    J Psychiatr Ment Health Nurs; 2016 Jun; 23(5):267-81. PubMed ID: 27037639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Psychoactive Substances and receding COVID-19 pandemic: really going back to "normal"?
    Napoletano S; Basile G; Lo Faro AF; Negro F
    Acta Biomed; 2022 May; 93(2):e2022186. PubMed ID: 35545997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Psychoactive Substances (NPS) - a Challenge for the Addiction Treatment Services.
    Scherbaum N; Schifano F; Bonnet U
    Pharmacopsychiatry; 2017 May; 50(3):116-122. PubMed ID: 28444659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deaths from novel psychoactive substances in England, Wales and Northern Ireland: Evaluating the impact of the UK psychoactive substances act 2016.
    Deen AA; Claridge H; Treble RD; Hamnett HJ; Copeland CS
    J Psychopharmacol; 2021 Nov; 35(11):1315-1323. PubMed ID: 34182812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New/emerging psychoactive substances and associated psychopathological consequences.
    Schifano F; Napoletano F; Chiappini S; Guirguis A; Corkery JM; Bonaccorso S; Ricciardi A; Scherbaum N; Vento A
    Psychol Med; 2021 Jan; 51(1):30-42. PubMed ID: 31327332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel psychoactive substances as a novel challenge for health professionals: results from an Italian survey.
    Simonato P; Corazza O; Santonastaso P; Corkery J; Deluca P; Davey Z; Blaszko U; Schifano F
    Hum Psychopharmacol; 2013 Jul; 28(4):324-31. PubMed ID: 23881880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Legal high industry business and lobbying strategies under a legal market for new psychoactive substances (NPS, 'legal highs') in New Zealand.
    Rychert M; Wilkins C
    Int J Drug Policy; 2016 Nov; 37():90-97. PubMed ID: 27639994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of new psychoactive substances in Northeast Asia from 2007 to 2015.
    Lee J; Yang S; Kang Y; Han E; Feng LY; Li JH; Chung H
    Forensic Sci Int; 2017 Mar; 272():1-9. PubMed ID: 28088088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scheduling of new psychoactive substance the Swiss way: A review and critical analysis.
    Grafinger KE; Bernhard W; Weinmann W
    Sci Justice; 2019 Jul; 59(4):459-466. PubMed ID: 31256819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detecting a signal in the noise: monitoring the global spread of novel psychoactive substances using media and other open-source information.
    Young MM; Dubeau C; Corazza O
    Hum Psychopharmacol; 2015 Jul; 30(4):319-26. PubMed ID: 26216568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoting innovation and excellence to face the rapid diffusion of novel psychoactive substances in the EU: the outcomes of the ReDNet project.
    Corazza O; Assi S; Simonato P; Corkery J; Bersani FS; Demetrovics Z; Stair J; Fergus S; Pezzolesi C; Pasinetti M; Deluca P; Drummond C; Davey Z; Blaszko U; Moskalewicz J; Mervo B; Furia LD; Farre M; Flesland L; Pisarska A; Shapiro H; Siemann H; Skutle A; Sferrazza E; Torrens M; Sambola F; van der Kreeft P; Scherbaum N; Schifano F
    Hum Psychopharmacol; 2013 Jul; 28(4):317-23. PubMed ID: 23881879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New psychoactive substances: concerted efforts and common legislative answers for stemming a growing health hazard.
    Zaami S
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9681-9690. PubMed ID: 31799633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New psychoactive substances: An actual problem or an overestimated phenomenon?
    Vaiano F; Pascali JP; Bertol E
    Forensic Sci Int; 2019 Nov; 304():109941. PubMed ID: 31574421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature.
    Chiappini S; Mosca A; Miuli A; Santovito MC; Orsolini L; Corkery JM; Guirguis A; Pettorruso M; Martinotti G; Di Giannantonio M; Schifano F
    Medicina (Kaunas); 2021 Jun; 57(6):. PubMed ID: 34204131
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug trends and harm related to new psychoactive substances (NPS) in Sweden from 2010 to 2016: Experiences from the STRIDA project.
    Helander A; Bäckberg M; Beck O
    PLoS One; 2020; 15(4):e0232038. PubMed ID: 32324788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What products are considered psychoactive under New Zealand's legal market for new psychoactive substances (NPS, 'legal highs')? Implications for law enforcement and penalties.
    Rychert M; Wilkins C
    Drug Test Anal; 2016 Aug; 8(8):768-78. PubMed ID: 26857892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.